Sort by
Keyphrases
Acute Effects
25%
Alzheimer's Disease
12%
Anti-inflammatory Effect
15%
Anti-neuroinflammation
25%
Anxiety-like Behavior
22%
Astroglial Cells
20%
Behavioral Deficits
27%
Behavioral Impairment
50%
Brain Hippocampus
17%
Brain Regions
17%
Brainstem
27%
C57BL
22%
Central System
12%
Cerebellum
27%
Chemokine (C-C motif) Ligand 2 (CCL2)
56%
Chemokine Expression
37%
Continuation Treatment
12%
CXCL10
45%
Differential Effects
22%
Dosing Schedule
13%
Enzyme-linked Immunosorbent Assay (ELISA)
25%
Expression Activity
25%
Female Mice
18%
Frontal Cortex
15%
Inflammation
55%
Inflammatory Chemokines
22%
Inflammatory Pathways
33%
Large Intestine
12%
Lipopolysaccharide
81%
Lipopolysaccharide-induced
100%
Liver
12%
Monocyte Chemoattractant protein-1 (MCP-1)
16%
Mu-opioid Receptor Antagonist
20%
Neuroinflammation
55%
Neurological Disorders
16%
Neuroprotective Effect
15%
Open Field Test
20%
Parkinson's Disease
12%
Peripheral Inflammation
12%
Potential Treatments
17%
Prefrontal Cortex
12%
Protective Effect
30%
Psychosocial Stress
13%
Sickness
40%
Sickness Behavior
25%
Small Intestine
12%
Social Defeat
25%
Treatment Development
12%
Two-way Analysis of Variance
16%
Whole Brain
30%
Neuroscience
Alzheimer's Disease
7%
Anti-Inflammatory
14%
Astrocyte
7%
Behavior (Neuroscience)
34%
Blood Plasma
30%
Brainstem
16%
CCL2
49%
Cerebellum
16%
Chemokine
52%
Corticosterone
5%
CXCL10
38%
Elevated Plus Maze
10%
Frontal Lobe
8%
Glial Fibrillary Acidic Protein
5%
Hippocampus
13%
In Vitro
14%
Inflammatory Bowel Disease
7%
Interleukin 6
8%
Lipopolysaccharide
100%
Monocyte Chemotactic Protein 1
11%
Naltrexone
5%
Narcotic Antagonist
14%
Neurological Disorder
9%
Neuroprotective Agent
12%
Parkinson's Disease
7%
Prefrontal Cortex
7%
Sickness Behavior
25%
Social Defeat
25%
Treatment Development
7%
μ-Opioid Receptor
16%
Pharmacology, Toxicology and Pharmaceutical Science
Alzheimer's Disease
9%
Anti-Inflammatory Drug
8%
Antiinflammatory Activity
9%
Beta Funaltrexamine
6%
C57BL 6 Mouse
6%
Chemokine
55%
Cytokine
8%
Disease
78%
Enzyme-Linked Immunosorbent Assay
15%
Gamma Interferon
5%
Gamma Interferon Inducible Protein 10
5%
Inflammation
48%
Inflammatory Bowel Disease
9%
Interferon
6%
Interleukin 6
12%
Lipopolysaccharide
100%
Lipopolysaccharide-Induced Neuroinflammation
34%
Monocyte Chemotactic Protein 1
10%
Mu Opiate Receptor Antagonist
15%
Naltrexone
5%
Neurologic Disease
13%
Neuroprotective Agent
15%
Parkinson's Disease
9%
Preclinical Study
9%
Tumor Necrosis Factor
12%